Kwan-Hwa Chi

Title: Kwan-Hwa Chi: Innovator in Radiolabeled Active Targeting Pharmaceutical Composition

Introduction

Kwan-Hwa Chi is a notable inventor based in Taoyuan County, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of radiolabeled active targeting compositions. With a total of 2 patents, his work focuses on enhancing therapeutic strategies for tumor treatment.

Latest Patents

Chi's latest patents include a radiolabeled active targeting pharmaceutical composition. This innovative composition consists of a bioconjugate and a radionuclide. The bioconjugate is made up of a biomolecule and a metal nanoparticle. The biomolecule is specifically designed to have an affinity for receptors on the surface of cell membranes, and it is selected from peptides and proteins. Additionally, the invention provides a method for evaluating thermal adjuvant therapy for tumors, along with a corresponding kit. This pharmaceutical composition is crucial for assessing tumor accumulation time, which aids in establishing optimal policies for radiofrequency- or laser-induced thermal adjuvant therapies.

Career Highlights

Throughout his career, Kwan-Hwa Chi has worked with esteemed organizations such as the Institute of Nuclear Energy Research and the Atomic Energy Council, Executive Yuan. He has also been associated with National Yang Ming Chiao Tung University, where he has contributed to research and development in his field.

Collaborations

Chi has collaborated with notable colleagues, including Hsin-Ell Wang and Chien-Chung Hsia. Their joint efforts have further advanced the research and applications of radiolabeled pharmaceutical compositions.

Conclusion

Kwan-Hwa Chi's innovative work in radiolabeled active targeting pharmaceutical compositions showcases his dedication to improving cancer treatment methodologies. His contributions are significant in the ongoing quest for effective therapeutic solutions.